Cardiff Oncology
CRDF
29 hedge funds and large institutions have $24.7M invested in Cardiff Oncology in 2020 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 5 closing their positions.
4,243% more capital invested
Capital invested by funds: $568K → $24.7M (+$24.1M)
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
61% more funds holding
Funds holding: 18 → 29 (+11)
19.12% more ownership
Funds ownership: 5.54% → 24.66% (+19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$3.26M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$2.05M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.21M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$834K |
| 5 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$355K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Elkhorn Partners
Omaha,
Nebraska
|
-$53.5K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$21K |
| 3 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$14.5K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$13K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$10.4K |
CRDF Hedge Fund Activity: Q2 2020 in Review
29 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2020, worth a combined $24.7M — up 4,243% from $568K a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CRDF positions and 5 closed out — a net gain of 11 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Caxton Corporation, opening a new position worth an estimated $3.26M. The largest seller was Elkhorn Partners, cutting an estimated $53.5K.
- 29 institutional investors held Cardiff Oncology (CRDF) as of Q2 2020, up from 18 in Q1 2020.
- Funds reported $24.7M of Cardiff Oncology stock for Q2 2020, up 4,243% quarter-over-quarter.
- 16 funds opened new Cardiff Oncology positions in Q2 2020 and 5 closed out, a net change of +11 holders.
- The largest Cardiff Oncology buyer in Q2 2020 was Caxton Corporation, an estimated $3.26M added.
- The largest Cardiff Oncology seller in Q2 2020 was Elkhorn Partners, an estimated $53.5K sold.
Based on aggregated 13F filings for Q2 2020.